Masimo CorporationMASI
▲ PositiveTechnologyrelevance
Masimo's own AI-powered opioid detection feature received FDA clearance, directly benefiting its product offering.
Danaher shares rose 2.8% in morning trading after its recently acquired subsidiary Masimo received FDA clearance for an artificial intelligence-enabled feature on its wearable patient monitoring platform. The approved feature is designed to detect opioid-induced respiratory depression. Danaher officially acquired Masimo in June 2026, expanding its footprint in specialty diagnostics and patient-monitoring technologies. The shares were trading at $194.71, up 3.1% from the previous close.
Masimo CorporationMasimo's own AI-powered opioid detection feature received FDA clearance, directly benefiting its product offering.
Danaher CorporationDanaher's subsidiary Masimo received FDA clearance for an AI-powered opioid detection feature, enhancing its product portfolio.